Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Articles

Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study

Michael Drozd, Mar Pujades-Rodriguez, Patrick J Lillie, Sam Straw, Ann W Morgan, Mark T Kearney, Klaus K Witte, Richard M Cubbon

Summary

Background Non-communicable diseases (NCDs) have been highlighted as important risk factors for COVID-19 mortality. However, insufficient data exist on the wider context of infectious diseases in people with NCDs. We aimed to investigate the association between NCDs and the risk of death from any infection before the COVID-19 pandemic (up to Dec 31, 2019).

Methods For this observational study, we used data from the UK Biobank observational cohort study to explore factors associated with infection death. We excluded participants if data were missing for comorbidities, body-mass index, smoking status, ethnicity, and socioeconomic deprivation, and if they were lost to follow-up or withdrew consent. Deaths were censored up to Dec 31, 2019. We used Poisson regression models including NCDs present at recruitment to the UK Biobank (defined by use of body-mass index) and self-reported hypertension, chronic heart disease, chronic respiratory disease, diabetes, cancer, chronic liver disease, chronic kidney disease, previous stroke or transient ischaemic attack, other neurological disease, psychiatric disorder, and chronic inflammatory and autoimmune rheumatological disease), age, sex, ethnicity, smoking status, and socioeconomic deprivation. Separate models were constructed with individual NCDs replaced by the total number of prevalent NCDs to define associations with multimorbidity. All analyses were repeated with non-infection-related death as an alternate outcome measure to establish differential associations of infection death and non-infection death. Associations are reported as incidence rate ratios (IRR) accompanied by 95% CIs.

Findings After exclusion of 9210 (1.8%) of the 502505 participants in the UK Biobank cohort, our study sample comprised 493295 individuals. During 5273731 person-years of follow-up (median 10.9 years) 27729 deaths occurred, of which 1385 (5%) were related to infection. Advancing age, male sex, smoking, socioeconomic deprivation, and all studied NCDs were independently associated with the rate of both infection death and non-infection death. Compared with White ethnicity, a pooled Black, Asian, and minority ethnicity group was associated with a reduced risk of infection death (IRR 0.64, 95% CI 0.56–0.73) and non-infection death (0.80, 0.75–0.86). Stronger associations with infection death than with non-infection death were observed for advancing age (age 65 years vs 45 years: 7.59, 95% CI 5.92–9.73, for infection death vs 5.21, 4.97–5.48, for non-infection death), current smoking (vs never smoking: 3.69, 3.19–4.26, vs 2.52, 2.44–2.61), socioeconomic deprivation (most vs least deprived quintile: 2.13, 1.78–2.56, vs 1.38, 1.33–1.43), class 3 obesity (vs non-obese: 2.21, 1.74–2.82, vs 1.55, 1.44–1.66), hypertension (1.36, 1.22–1.53, vs 1.15, 1.12–1.18), respiratory disease (2.21, 1.96–2.50, vs 1.28, 1.24–1.32), chronic kidney disease (5.04, 4.28–7.31, vs 2.50, 2.20–2.84), psychiatric disease (1.56, 1.30–1.86, vs 1.23, 1.18–1.29), and chronic inflammatory and autoimmune rheumatological disease (2.45, 1.99–3.02, vs 1.41, 1.32–1.51). Accrual of multimorbidity was also more strongly associated with risk of infection death (five or more comorbidities vs none: 9.53, 6.97–13.03) than of non-infection death (5.26, 4.84–5.72).

Interpretation Several NCDs are associated with an increased risk of infection death, suggesting that some of the reported associations with COVID-19 mortality might be non-specific. Only a subset of NCDs, together with the accrual of multimorbidity, advancing age, smoking, and socioeconomic deprivation, were associated with a greater IRR for infection death than for other causes of death. Further research is needed to define why these risk factors are more strongly associated with infection death, so that more effective preventive strategies can be targeted to high-risk groups.

Funding British Heart Foundation.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction Non-communicable diseases (NCDs) have been highlighted as important risk factors for fatal SARS-CoV-2 infection.1,2 With use of the OpenSAFELY primary care health analytics platform based in England, increased risk of COVID-19 death has been independently associated with advancing age, male sex, non-White ethnicity, socioeconomic deprivation, and many NCDs, including
the following: severe obesity; diabetes; recently diagnosed cancer; chronic respiratory, cardiac, kidney, and liver disease; neurological disorders, including stroke and dementia; and rheumatological disorders.1 Similar conclusions were reached by Docherty and colleagues in an analysis of people hospitalised due to COVID-19 in England and Wales,3 specifically finding that death was associated with advancing age, male sex, chronic respiratory, cardiac, kidney, and liver disease, neurological disease, cancer, and obesity (but not diabetes). These data have prompted hypotheses that SARS-CoV-2 specifically interacts with some comorbidities.4–6 However, the wider context of infectious diseases in people with NCDs is likely to become more important in the context of globally increasing rates of multimorbidity and antimicrobial resistance.8,9

NCDs can be the sequelae of infectious diseases—for example, as a result of carcinogenesis or chronic organ dysfunction—but are also important risk factors for fatal acute infection—for example, as a result of sepsis or acute organ dysfunction. The Global Burden of Disease Study revealed that 11 million sepsis-related deaths occurred during 2017, amounting to almost 20% of all deaths.7 Sepsis-related death was more common in men, older individuals (and infants), and socioeconomically deprived populations. Moreover, about 40% of cases had an NCD listed as the underlying cause of death, with cardiovascular diseases, diabetes, liver disease, chronic obstructive pulmonary disease, and kidney disease all being commonly implicated. Hence, clear parallels can be seen between the risk factors for sepsis death and COVID-19 death.

Despite a 30% reduction in global sepsis-related deaths between 1990 and 2017,7 the issue of life-threatening infection in people with NCDs is likely to become more important in the context of globally increasing rates of multimorbidity and antimicrobial resistance.8,9 Moreover, as populations become more affluent, NCDs are proportionally more common as an underlying cause of sepsis death,7 underlining the growing relevance to many economically developing populations. Despite the scale and impact of this issue, little prospective research is published about the independent and additive risks posed by specific NCDs, and multimorbidity, for acute infection-related death. To address this gap, we investigated the association between NCDs and the risk of death from any infection by analysing the well characterised UK Biobank cohort study using follow-up data to the end of 2019 (before the COVID-19 pandemic).

Methods

Study design and data collection

For this observational study, we used data from the UK Biobank cohort, a population-based prospective study that consists of 502,505 people aged 37–73 years. The resource was developed with use of funding from the UK Government and biomedical research charities to improve understanding of disease, and it is an open access resource for all researchers. Full details of the study design and conduct are available at the UK Biobank website. Participants were recruited between 2006 and
2010, and attended one of 22 assessment centres across England, Scotland, and Wales; although the cohort is not representative of the whole UK population regarding socioeconomic deprivation, some NCDs, and ethnic minorities, it allows the assessment of exposure–disease relationships. Baseline biological measurements were recorded, and participants completed a touchscreen and nurse-led questionnaire, as described elsewhere. UK Biobank received ethical approval from the National Health Service (NHS) Research Ethics Service (11/NW/0382), and we did this analysis under application number 59585. All participants provided written informed consent. There was no patient or public involvement in the planning of this analysis and no prespecified analysis plan is published.

Assessment of demographic factors and morbidity
Age, sex, ethnicity, and socioeconomic status were defined at recruitment to UK Biobank and were considered as potential risk factors for death. Ethnicity was participant-classified within UK Biobank-defined categories of White, Mixed, Asian or British Asian, Black or British Black, Chinese, or other ethnic groups; due to the small number of people (and deaths) in each non-White ethnic group, these were pooled into a Black, Asian, and minority ethnic (BAME) group in most analyses, although they were considered separately in a sensitivity analysis. Smoking status was self-reported as never, former, or current at the point of recruitment. Socioeconomic deprivation was measured with the Townsend score and categorised into quintiles. Obesity was classified using WHO’s categorisation according to body-mass index: class 1 (30·0–34·9 kg/m²), class 2 (35·0–39·9 kg/m²), and class 3 (≥40 kg/m²). Self-reported medical conditions recorded solely at study recruitment during face-to-face interview with a nurse were used to classify morbidities into groups (appendix pp 1–2). We used clinical consensus before our analyses to select a range of morbidities representing a broad spectrum of common disease groups, including the following: hypertension, chronic heart disease (ischaemic heart disease and heart failure), chronic respiratory disease, diabetes, previous cancer, chronic liver disease, chronic kidney disease, previous stroke or transient ischaemic attack, other neurological disease, psychiatric disorder, and rheumatic disease. The number of comorbidities was calculated for each participant. Participants were excluded from the analysis if they had missing data for comorbidities. Participants were also excluded if they were lost to follow-up or withdrew consent.

Mortality ascertainment
Mortality information was provided by the UK Biobank data portal, which uses linked national death registry data from NHS Digital for participants in England and Wales and from the NHS Central Register, part of the National Records of Scotland, for participants in Scotland. In our analysis, we censored deaths up until Dec 31, 2019, to ensure included deaths occurred before the first reported case of COVID-19 in the UK. Using codes from the International Classification of Diseases (tenth revision), we classified the main cause of death as infection related or non-infection related (appendix pp 3, 17–43).

Statistical analysis
Continuous variables are presented as mean (SD) or median (IQR) if non-normally distributed, and categorical variables are presented as number (%). We plotted Kaplan-Meier curves to illustrate mortality rates. Absolute rates of death observed in specific categories of participants were defined by dividing the number of observed deaths in each category by the respective duration of follow-up, and expressed per 1000 person-years. We estimated adjusted cause-specific mortality incidence rate ratios (IRRs) using Poisson regression models; exposure time was modelled, but time-varying covariates were not used, and the calendar year of recruitment was not included in models because of the narrow recruitment period. Models were adjusted for all covariates, including age, sex, socioeconomic deprivation quintile, smoking status, obesity, hypertension, chronic heart disease, chronic respiratory disease, diabetes, cancer (previous or current), chronic liver disease, chronic kidney disease, previous stroke or transient ischaemic attack, other neurological disease, psychiatric disorder, and rheumatological disease. We used correlation matrices of Poisson model’s coefficients to assess correlations between covariates; no correlation coefficients higher than 0·3 or lower than −0·3 were observed. To assess the association of multimorbidity with infection death, irrespective of the specific morbidities, we also separately modelled the number of comorbidities (up to a maximum of five, because few participants had six or more, limiting confidence in estimates) in place of the individual comorbidity variables. We modelled age using restricted cubic splines with five knots for infection death analyses and four knots for non-infection death analyses, because these provided the best fit as assessed by the Akaike information and the Bayesian criterion (models including categorical, linear, or cubic splines with three, four, and five knots and first-degree and second-degree fractional polynomials were compared). Therefore, presented IRR estimates for age pertain to specific age points (50, 55, 60, and 65 years, compared with 45 years), not an age category (appendix p 15).

We did several sensitivity analyses. First, we assessed unadjusted models; models adjusted for age and sex; models adjusted for age, sex, and demographic factors; and fully adjusted models. Second, we assessed Mixed, Asian or British Asian, Black or British Black, Chinese, and other ethnicity as individual groups, rather than pooling them into a single BAME group. Third, we compared risk of death (infection and non-infection) by
lower respiratory tract infection versus other infection. Fourth, we excluded deaths occurring after 5 years or 9 years of recruitment, which might have been caused by NCDs diagnosed after recruitment to the UK Biobank cohort. And fifth, we assessed age-adjusted and sex-adjusted models in the study cohort (excluding individuals from the UK Biobank cohort with missing data) versus the full UK Biobank cohort. We used quantitative bias analysis using e-values14 to define the degree of unmeasured confounding that would be required to nullify observed associations between socioeconomic deprivation and infection death. All tests were two-sided and statistical significance was defined as p<0·05. All statistical analyses were done with Stata/MP (version 16.1).

Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results
Among the UK Biobank cohort of 502505 people, we excluded 9210 (1·8%) because of missing baseline data or long-term follow-up data. These included exclusions due to missing data for comorbidities (863 individuals), body-mass index (3106 individuals), smoking status (2949 individuals), ethnicity (2777 individuals), and socioeconomic deprivation quintile (624 individuals), and individuals lost to follow-up or who withdrew consent (1298 individuals). These exclusions resulted in a study sample of 493295 people. In the study cohort, 1385 infection deaths occurred before Dec 31, 2019, during 5273731 person-years of follow-up (median 10·9 years [IQR 10–11·6] per participant), accounting for 5% of the total 27729 deaths (figure 1A, appendix p 16). The most common fatal infections involved the lower respiratory tract (840 events [60–6%]), gastrointestinal tract (196 events [14–2%]), and genitourinary tract (82 events [5–9%]); data for all causes are presented in figure 1B and the appendix (p 4). Compared with survivors, people who died with infection were older, more often men, more socioeconomically deprived, more commonly current or former smokers, and more likely to have a wide range of NCDs (table 1). Broadly similar differences were observed when comparing survivors with people who died from causes other than infection, although cancer was markedly more common in people who died from non-infection causes than in people who died from infection. Absolute rates of infection and non-infection death per 1000 person-years are shown in table 2.

By assessing IRRs for the association between NCDs and infection death, we found that advancing age, male sex, severe obesity, smoking, socioeconomic deprivation, and all individual NCDs were independently associated with the risk of infection death (figure 2; unadjusted models and models adjusted for age and sex or age, sex, and demographics are shown in appendix pp 5–6). However, BAME was associated with a lower risk of infection death than White ethnicity (IRR 0·64, 95% CI 0·46–0·87), with IRRs remaining below 1 when individual BAME groups were modelled, although with 95% CIs crossing 1 (appendix pp 7–8). Advancing age, male sex, obesity, smoking, socioeconomic deprivation, and all individual NCDs were also independently associated with increased risk of non-infection death; however, BAME was again associated with lower risk (0·80, 0·75–0·86; figure 2). Only the following factors were associated with greater IRRs for infection than for non-infection death: current smoking, socioeconomic deprivation, class 3 obesity, hypertension, chronic respiratory disease, chronic kidney disease, psychiatric disease, and chronic inflammatory and autoimmune rheumatological disease (figure 2). By contrast, cancer was associated with a greater risk of non-infection death than infection death (figure 2).

Because lower respiratory tract infection accounted for the majority of infection deaths in our analysis (figure 1B,
**Table 1: Participant characteristics at study recruitment**

| SED quintile       | Age, years | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|---------------------|------------|-----------------------|--------------------------|-------------------------------|
| 1 (least deprived) | <45        | 50,081 (10.8%)        | 23 (1.7%)                | 599 (2.3%)                    |
|                     | 45 to <50  | 63,617 (13.7%)        | 40 (2.9%)                | 1,205 (4.6%)                  |
|                     | 50 to <55  | 72,681 (15.6%)        | 103 (7.4%)               | 2,164 (8.2%)                  |
|                     | 55 to <60  | 85,185 (18.3%)        | 195 (14.1%)              | 3,881 (14.7%)                 |
|                     | 60 to <65  | 111,064 (23.9%)       | 383 (27.7%)              | 7,924 (30.1%)                 |
|                     | ≥65        | 82,936 (17.8%)        | 641 (46.3%)              | 10,574 (40.1%)                |

**Sex**

|                | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|----------------|-----------------------|--------------------------|-------------------------------|
| Men            | 207,883 (44.7%)      | 842 (60.8%)               | 15,712 (59.6%)                |
| Women          | 257,683 (55.3%)      | 543 (39.2%)               | 10,632 (40.4%)                |

**Ethnicity**

|                | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|----------------|-----------------------|--------------------------|-------------------------------|
| White          | 440,402 (94.6%)      | 1,344 (97.0%)            | 25,453 (96.6%)                |
| Mixed          | 7,397 (0.6%)         | 4 (0.3%)                 | 104 (0.4%)                    |
| Asian          | 9106 (2.0%)          | 19 (1.4%)                | 338 (1.3%)                    |
| Black          | 7534 (1.6%)          | 12 (0.9%)                | 249 (0.9%)                    |
| Chinese        | 1502 (0.3%)          | 1 (0.1%)                 | 37 (0.1%)                     |
| Other          | 4225 (0.9%)          | 5 (0.4%)                 | 163 (0.6%)                    |

**Table 2: Absolute unadjusted rates of infection death and non-infection death per 1000 person-years of follow-up according to baseline characteristics**

| Age, years | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|------------|-----------------------|--------------------------|-------------------------------|
| <45        | 0.04 (0.03-0.06)      | 1.08 (1.00-1.17)         |
| 45 to <50  | 0.06 (0.04-0.08)      | 1.71 (1.61-1.81)         |
| 50 to <55  | 0.13 (0.10-0.15)      | 2.66 (2.55-2.78)         |
| 55 to <60  | 0.20 (0.18-0.23)      | 4.04 (3.91-4.17)         |
| 60 to <65  | 0.30 (0.27-0.33)      | 6.26 (6.13-6.40)         |
| ≥65        | 0.66 (0.61-0.71)      | 10.81 (10.61-11.03)      |

**Sex**

|                | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|----------------|-----------------------|--------------------------|-------------------------------|
| Men            | 0.35 (0.33-0.38)      | 6.60 (6.49-6.70)         |
| Women          | 0.19 (0.17-0.20)      | 3.68 (3.61-3.75)         |

**Ethnicity**

|                | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|----------------|-----------------------|--------------------------|-------------------------------|
| White          | 0.27 (0.25-0.28)      | 5.09 (5.03-5.15)         |
| BAME           | 0.15 (0.11-0.20)      | 3.27 (3.06-3.49)         |

**SED quintile**

| SED quintile | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|--------------|-----------------------|--------------------------|-------------------------------|
| 1 (<60)      | 93,973 (20.2%)        | 170 (12.3%)               | 4,555 (17.3%)                 |
| 2            | 93,776 (20.1%)        | 206 (14.9%)               | 4,640 (17.2%)                 |
| 3            | 93,483 (20.1%)        | 240 (17.3%)               | 4,936 (18.7%)                 |
| 4            | 93,112 (20.0%)        | 295 (21.3%)               | 5,254 (19.9%)                 |
| 5 (>60)      | 91,222 (19.6%)        | 474 (34.2%)               | 5,959 (26.4%)                 |

**Smoking**

|                | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|----------------|-----------------------|--------------------------|-------------------------------|
| Never          | 259,721 (55.8%)       | 433 (31.7%)               | 10,072 (38.2%)                |
| Former         | 159,304 (34.2%)       | 582 (42.0%)               | 11,128 (42.2%)                |
| Current        | 46,541 (10.0%)        | 364 (26.3%)               | 5,144 (19.5%)                 |

**Obesity**

|                | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|----------------|-----------------------|--------------------------|-------------------------------|
| Not obese      | 352,374 (75.7%)       | 928 (67.0%)               | 18,206 (69.1%)                |
| Class 1        | 81,466 (17.5%)        | 1281 (20.3%)              | 4,741 (20.8%)                 |
| Class 2        | 22,992 (4.9%)         | 96 (6.9%)                 | 1,828 (8.9%)                  |
| Class 3        | 8734 (1.9%)           | 80 (5.9%)                 | 892 (4.2%)                    |

**Hypertension**

|                | Survivors (n=465,566) | Infection death (n=1385) | Non-infection death (n=26,344) |
|----------------|-----------------------|--------------------------|-------------------------------|
| Class 1        | 195,673 (42.4%)       | 250 (18.1%)               | 3,544 (13.5%)                 |
| Class 2        | 59,068 (12.7%)        | 385 (28.7%)               | 4,451 (16.9%)                 |
| Diabetes       | 21,206 (4.6%)         | 228 (16.5%)               | 3,317 (12.6%)                 |
| Cancer         | 35,818 (7.7%)         | 127 (18.2%)               | 4,012 (15.9%)                 |
| Chronic liver  | 797 (0.2%)            | 12 (0.9%)                 | 147 (0.6%)                    |
| Chronic kidney | 1,001 (0.2%)          | 29 (2.1%)                 | 241 (0.9%)                    |
| Previous stroke| 7214 (1.5%)           | 104 (7.5%)                | 1,274 (4.8%)                  |
| Other neurological | 5,726 (1.2%)       | 57 (4.1%)                 | 763 (2.9%)                    |

For table 1, appendix p 4, we did a sensitivity analysis evaluating the association between NCDs and risk of death from lower respiratory tract infection or from other infections (appendix p 9). Current smoking and chronic respiratory disease were associated with a greater risk of death from lower respiratory tract infection than from other infection. The large 95% CIs in this analysis preclude robust comparisons, but advancing age, male sex, and increasing
socioeconomic deprivation were also associated with nominally larger risks of death from lower respiratory tract infection than from other infection. An additional sensitivity analysis excluding deaths occurring after 5 years or 9 years of follow-up showed associations of similar magnitude between NCDs and infection or non-infection death over time (appendix p 10). Given that 9210 people (56 deaths) from the full UK Biobank cohort were excluded from our analyses because of missing data, we also report results of models adjusted for age and sex done separately for the full UK Biobank population and for our study population (appendix pp 11–12). These models showed almost identical associations between NCDs and infection or non-infection death, suggesting that the exclusion of 9210 people did not substantially bias our estimates.

Finally, to explore the effect of multimorbidity, we did alternate analyses including the number of NCDs rather than individual diseases, while also accounting for age, sex, smoking status, ethnicity, and socioeconomic deprivation quintile. This analysis showed increasing risk of infection death as the number of NCDs increased (figure 3; appendix p 13, including unadjusted models and models adjusted for age and sex). Notably, although an increasing risk of non-infection death with increasing multimorbidity was also observed, this increase was less steep than that for infection death.

**Discussion**

To our knowledge, this study reports the largest prospective analysis of risk factors for infection death in people recruited in a community setting. Infection death was more common in men, with advancing age, and with increasing socioeconomic deprivation. All studied NCDs were also independently associated with increased risk of infection death, as was the accrual of multimorbidity. Except for ethnicity, risk factors for infection death were similar to those reported for COVID-19 death, with generally similar IRRs for infection and non-infection death observed. However, some factors conferred greater risk of infection death than of non-infection death, including advancing age, smoking status, increasing socioeconomic deprivation, class 3 obesity, hypertension, chronic respiratory disease, chronic kidney disease, psychiatric disease, chronic inflammatory and autoimmune rheumatological disease, and the accrual of multimorbidity. These high-risk populations might benefit from strategies to prevent or more effectively treat infections.

The existing literature supports the importance of infection as a cause of death in populations with many of the NCDs we have studied, including in people with chronic heart failure, diabetes, chronic kidney disease, liver disease, rheumatological disease, and neurodegenerative disorders. Our analysis supports these disease-specific data, but it has the advantage of considering both the additive and independent risk of infection death attributable to multiple NCDs in the same population. Notably, although the accumulation of multimorbidity has been linked with increased risks of all-cause, cardiovascular, and cancer death, our finding that accumulation of multimorbidity was associated with a greater risk of infection death than of non-infection death is novel. Regarding the larger hazard of infection death associated with socioeconomic deprivation, it is notable that socioeconomic interventions have had major roles in addressing past and present infectious diseases.
diseases. Although residual confounding relating to unmeasured associates of deprivation could explain this association, this would need to be strong to remove the link because an exploratory quantitative bias analysis of the IRR for infection death comparing socioeconomic deprivation quintile 5 versus 1 (2·13, 95% CI 1·78–2·56; appendix p 5) yielded an e-value of 3·68 (95% CI 2·96–4·56).

The COVID-19 pandemic has brought fresh attention to the association between NCDs and infectious diseases. Although some disagreements exist regarding specific risk factors (probably reflecting study design), the COVID-19 literature broadly suggests that older age, male sex, socioeconomic deprivation, and accrual of NCDs increase the risk of adverse outcomes. This broad agreement with our analysis of risk factors for death related to infection in the pre-COVID-19 era suggests common underlying factors and solutions to these problems. One notable difference was that a pooled BAME group was associated with reduced risk of infection death compared with White ethnicity in our adjusted analyses, but it has frequently been identified as a risk factor for adverse COVID-19 outcomes, including in the UK Biobank cohort. Although the association in our analysis was significant, our data assessing the association of BAME with outcomes come from a reasonably small number of people and events (26 096 people, with 891 non-infection deaths and 41 infection deaths), and the UK Biobank is not representative of UK ethnic minorities. These limitations can translate into less precise estimates, especially for individual ethnic groups, as illustrated by our sensitivity analysis including individual ethnic groups (appendix pp 7–8), which exhibited non-significantly reduced IRRs for infection death with very broad confidence intervals. However, our data raise the possibility that the adverse COVID-19 outcomes of BAME groups are not explained by a more generalised susceptibility to infection death.

This study has some limitations. First, UK Biobank is not a nationally representative cohort (particularly relating to socioeconomic deprivation, some NCDs, and ethnic minorities), thus caution should be used when extrapolating data on infection death prevalence. Moreover, although our finding that infections accounted for about 5% of all deaths is broadly in keeping with Global Burden of Disease data for the UK, a nationally unrepresentative case-mix means that our risk estimates might be less valid or precise when applied to the general population. We should also highlight the challenges of death certification data, which do not always encompass the complex factors contributing to death. Similarly, the classification of NCD status in the UK Biobank often relies on participant-reported data and was available only at the point of recruitment (as was smoking and deprivation data), so it might not have the fidelity of other approaches and could result in underestimation of the magnitude of associations studied. Although self-reported diabetes data in the UK Biobank have shown reasonable agreement with care records, we should note that this concordance has not been studied for most NCDs and the proportion of people with NCDs is lower in UK Biobank than in the age-matched and sex-matched UK population (appendix p 14). Moreover, the classification of most NCDs as being either present or absent neglects the heterogeneity that exists within NCDs, which might have an important influence on risk of infection death. Such misclassification of exposures (and outcome measures) might lead to underestimation of risk estimates. Regarding potentially important missing variables, we were unable to consider the number, nature, or volume of person-to-person contacts, which is particularly relevant to infectious diseases; and we were also unable to comment on the nature of pathogens (eg, bacterial or viral) because the causative pathogen is often not clinically ascertained or recorded. Finally, as with any observational study, it is important not to draw causal inferences from our data, although our findings raise many important and testable hypotheses.

Ongoing work is needed to understand the relative importance of NCDs causing recurrent infections versus increasing the risk of death during any single episode to the overall risk of infection death. Future research should also define mechanisms linking NCDs (and their treatment) to infection death—for example, through altered immune responses to vaccination and infection, inflammatory responses to pathogens, and physiological responses during infection or sepsis. Addressing these uncertainties will help to inform the selection of therapeutic strategies for clinical trials. These could include specific primary and secondary infection prevention measures; improved access to care, monitoring for early detection of infection, and initiation of
appropriate antimicrobial treatment; and improved use of high-dependency care. Our data emphasise that research addressing the interaction between infections and NCDs will be important even in a post-COVID-19 era.

**Contributors**

MD and RMC conceived the study and drafted the manuscript. MD and MP-R analysed the data. P/JL, MP-R, AW, SS, MTK, and KKW critically revised the manuscript. MD and RMC verified the data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. RMC attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

**Declaration of interests**

AWM has undertaken consultancy work in relation to giant cell arteritis for Roche, Chugui, GlaxoSmithKline, Sanofi, and Regeneron Pharmaceuticals, with all funding paid directly into a research account. MTK has received speaker fees from Merck and Novo Nordisk and unrestricted research awards from Medtronic. KKW has received speaker fees from Medtronic, Microport, Abbott, Pfizer, Bayer, and BMS. All other authors declare no competing interests.

**Data sharing**

The UK Biobank resource is open to all researchers (https://www.ukbiobank.ac.uk).

**Acknowledgments**

This research has been done with use of the UK Biobank resource, under application 59585. MD is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/12/80/29821). Foundation Professor. RMC was supported by a British Heart and the UK Medical Research Council. MTK is a British Heart Clinical Research Training Fellowship (FS/18/44/33792). A WM has under application 59585. MD is supported by a British Heart Foundation unrestricted research awards from Medtronic. KKW has received fees for Roche, Chugai, GlaxoSmithKline, Sanofi, and Regeneron Pharmaceuticals. All other authors declare no competing interests.

**References**

1. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature 2020; 584: 430–36.
2. Pettiti CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966.
3. Docherty AB, Harrison EM, Green CA, et al. Features of 2019 novel coronavirus disease 2019 in New York City: an observational cohort study. BMJ 2020; 369: m3022.
4. De Lorenzo A, Escobar S, Tihrińčič E. Systemic endothelial dysfunction: a common pathway for COVID-19, cardiovascular, and metabolic diseases. Nutr Metab Cardiovasc Dis 2020; 30: 1401–02.
5. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020; 395: 1517–20.
6. Cinti S, Gracciotti L, Giordano A, Valerio A, Nisoli E. COVID-19 and fat embolism: a hypothesis to explain the severe clinical outcome in people with obesity. Int J Obes 2020; 44: 1800–02.
7. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395: 200–11.
8. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis 2013; 13: 1057–98.
9. Garin N, Koyanagi A, Chatterji S, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci 2015; 71: 205–14.
10. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol 2017; 186: 1026–34.
11. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12: 1–10.
12. Jari BD, Hanlon P, Nicholl B, et al. Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. BMC Med 2019; 17: 74.
13. Moss P, Barlow G, Easom N, Lillie P, Samson A. Lessons for managing high-consequence infections from first COVID-19 cases in the UK. Lancet 2020; 395: e46.
14. Drozd M, Garland E, Walker AMN, et al. Infection-related hospitalization in heart failure with reduced ejection fraction. Circ Heart Fail 2020; 13: e006746.
15. Walker A, Drozd M, Hall M, et al. Prevalence and predictors of sepsis death in patients with chronic heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc 2018; 7: e009684.
16. Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care 2018; 41: 513–21.
17. Wang HE, Gambou C, Warnock DG, Munter P. Chronic kidney disease and risk of death from infection. Am J Nephrol 2011; 34: 130–36.
18. Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246–56.
19. Wu J, Keeley A, Mallen C, Morgan AW, Pujades-Rodriguez M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. CMAJ 2019; 191: E680–88.
20. Manabe T, Fujikura Y, Mizukami K, Akatsu H, Kudo K. Pneumonia-associated death in patients with dementia: a systematic review and meta-analysis. PLoS One 2019; 14: 1–14.
21. Brazenor P. Accumulating knowledge on the social determinants of health and infectious disease. Public Health Rep 2011; 126 (suppl 3): 28–30.
22. Semenza JC, Suk JE, Tisołova S. Social determinants of infectious diseases: a public health priority. Eurosurveillance 2010; 15: 2–4.
23. VanderWeele T, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 2017; 167: 268–74.
24. Patel P, Hiam I, Sowemimo A, Devakumar D, Mckee M. Ethnicity and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. BMC Med 2020; 18: 160.
25. Eastwood S V, Mathur R, Atkinson M, et al. Algorithms for the capture and adjudication of prevalent and incident diabetes in UK Biobank. PLoS One 2016; 11: 1–18.